ReviewEuropean journal of pediatrics2011
Biologics in children's autoimmune disorders: efficacy and safety.
Review in European journal of pediatrics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 55 citations in OpenAlex.
- Tuberculosis in children and adolescents using biological agents: a nationwide cohort study from Turkey.BMC pulmonary medicine · 2025Article
- A Theoretical Link Between the GH/IGF-1 Axis and Cytokine Family in Children: Current Knowledge and Future Perspectives.Children (Basel, Switzerland) · 2025Review
- Biological Agents' Adverse Events in Jordanian Childhood Rheumatic Diseases: A Single-Center Experience.Cureus · 2025Article
- How Safe Are Biological Agents in Pediatric Rheumatology?Turkish archives of pediatrics · 2024Article
- The vaccine coverage and vaccine immunity status and risk factors of non-protective levels of antibodies against vaccines in children with juvenile idiopathic arthritis: cross-sectional Russian tertiary Centre study.Pediatric rheumatology online journal · 2021Article
- Disease-modifying therapies and infectious risks in multiple sclerosis.Nature reviews. Neurology · 2016Review
- [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].Der Nervenarzt · 2015Article
- Neutralizing anti-interleukin-1β antibodies modulate fetal blood-brain barrier function after ischemia.Neurobiology of disease · 2015Article
- Immunization of children with secondary immunodeficiency.Human vaccines & immunotherapeutics · 2015Review
- A successful treatment of juvenile idiopathic arthritis with rituximab: A report of two cases.European journal of rheumatology · 2014Article
- Juvenile idiopathic arthritis: management and therapeutic options.Therapeutic advances in musculoskeletal disease · 2012Article
- Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions.Adolescent health, medicine and therapeutics · 2012Review
- TNF-α Polymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications?International journal of rheumatology · 2012Article
- Fatal group A Streptococcus purpura fulminans in a child receiving TNF-α blocker.European journal of pediatrics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in understanding the pathogenesis of rheumatic diseases have led to the discovery of mechanisms of inflammation and autoimmunity and have made possible the invention of new target-specific drugs. Biologic drugs, designed to inhibit specific components of the immune system, such as cytokines, cytokine gene expression, and their complex interactions, have revolutionized the treatment options in pediatric rheumatology. Only three agents are currently available for treating juvenile idiopathic arthritis (JIA): etanercept, at the dose of 0.8 mg/kg once weekly, adalimumab at the dose of 24 mg/m(2) every 2 weeks, and abatacept at the dose of 10 mg/kg at weeks 0, 2, 4, and then every 4 weeks. They are well tolerated and relatively safe in children: Side effects are generally mild and include injection site reactions and infections. Infliximab, rilonacept, and canakinumab are also approved by the Food and Drug Administration for treatment of pediatric autoimmune disorders and are currently investigated in JIA. This review summarizes the current state of biologic drugs, their clinical application, and their efficacy and safety in the pediatric age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.